Literature DB >> 14529383

Structure and functional relationships of Hsp90.

Chrisostomos Prodromou1, Laurence H Pearl.   

Abstract

Understanding the mode of action of Hsp90 requires that molecular detail of its interactions with client proteins and co-chaperones are known. The structure determination of the N-terminal domain of Hsp90/Hsp90beta, proof that it is an ATPase, that this activity is regulated and the identification of co-chaperones that facilitate Hsp90 function were landmarks towards understanding conformational changes in Hsp90 brought about by ATP, co-chaperones and client proteins. Sti1 and Cdc37/p50, which associate with early Hsp90 complexes, were shown to be inhibitors of Hsp90 ATPase activity and therefore promote its 'open' state, whereas Sba1/p23, which associates with mature complexes, inhibits ATPase activity and stabilises the 'closed' state. The isolation and characterisation of Aha1, the only known strong activator of Hsp90 ATPase activity, which promotes the 'closed' state of Hsp90, will also be of major importance in understanding Hsp90 function. The structure determination of the middle region of Hsp90 has shed further light on the complex ATP-cycle of Hsp90, identifying a catalytic loop, with key residues that are essential for ATP hydrolysis. These studies, together with biochemical ones, suggest that ATP hydrolysis, is dependent on a complex rate-limiting step, involving N-terminal dimerization and association of the middle region, and therefore the catalytic loop, of Hsp90 with the N-terminal domains. The structure of the middle region of Hsp90 will also accelerate our understanding of client protein interactions since this region is implicated in their recognition and in particular their active-site openings.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529383     DOI: 10.2174/1568009033481877

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  86 in total

1.  Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain.

Authors:  Simona Tomaselli; Massimiliano Meli; Janet Plescia; Lucia Zetta; Dario C Altieri; Giorgio Colombo; Laura Ragona
Journal:  Chem Biol Drug Des       Date:  2010-11       Impact factor: 2.817

2.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 3.  Macrocyclic inhibitors of hsp90.

Authors:  Victoria A Johnson; Erinprit K Singh; Lidia A Nazarova; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 4.  Post-translational modifications of Hsp90 and translating the chaperone code.

Authors:  Sarah J Backe; Rebecca A Sager; Mark R Woodford; Alan M Makedon; Mehdi Mollapour
Journal:  J Biol Chem       Date:  2020-06-11       Impact factor: 5.157

5.  Hsp90 cochaperone Aha1 is a negative regulator of the Saccharomyces MAL activator and acts early in the chaperone activation pathway.

Authors:  Fulai Ran; Nidhi Gadura; Corinne A Michels
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

Review 6.  Tetratricopeptide repeat cochaperones in steroid receptor complexes.

Authors:  David F Smith
Journal:  Cell Stress Chaperones       Date:  2004       Impact factor: 3.667

7.  Effect of mutation of the tetratricopeptide repeat and asparatate-proline 2 domains of Sti1 on Hsp90 signaling and interaction in Saccharomyces cerevisiae.

Authors:  Gary Flom; Janae Weekes; Julia J Williams; Jill L Johnson
Journal:  Genetics       Date:  2005-10-11       Impact factor: 4.562

Review 8.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

9.  Alteration of the protein kinase binding domain enhances function of the Saccharomyces cerevisiae molecular chaperone Cdc37.

Authors:  Min Ren; Arti Santhanam; Paul Lee; Avrom Caplan; Stephen Garrett
Journal:  Eukaryot Cell       Date:  2007-06-15

10.  Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37.

Authors:  Yoshihiko Miyata; Eisuke Nishida
Journal:  Mol Cell Biochem       Date:  2008-06-20       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.